Literature DB >> 11196509

Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.

S Lakshminarayanan1, S Walsh, M Mohanraj, N Rothfield.   

Abstract

OBJECTIVE: To study risk factors for low bone mineral density (BMD, g/cm) in patients with systemic lupus erythematosus (SLE).
METHODS: Ninety-two consecutive patients with SLE followed by rheumatology faculty between 1997 and 1999 completed a questionnaire regarding lifestyle during the clinic visit, a chart review was performed, and data were collected for the time of the first dual energy x-ray absorptiometry (DXA) examination. Univariate and multivariate statistical analyses were used to assess relationships between various risk factors and BMD.
RESULTS: Ninety-eight percent of patients had received prednisone, 51% were postmenopausal (9 of whom received hormone replacement therapy), 68% had received hydroxychloroquine, and 15% were osteoporotic. The following factors were found to be significantly related to lower BMD by univariate analysis: Caucasian race, older age at diagnosis, higher age at the time of the first DXA, longer disease duration, higher cumulative corticosteroid dose, higher SLE Damage Index score, and postmenopausal status. In the multivariate analysis only the following factors were significant: Caucasian race, increased number of pregnancies, postmenopausal status, higher SLE Damage Index, and higher cumulative corticosteroid dose. An unexpected finding was that taking hydroxychloroquine was the only factor associated with higher BMD of the hip and spine in the univariate analysis, and it remained predictive of higher BMD of the hip and spine in the multivariate analysis.
CONCLUSION: Hydroxychloroquine appears to protect against low BMD in corticosteroid treated patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196509

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  36 in total

Review 1.  How to monitor SLE in routine clinical practice.

Authors:  M M A Fernando; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

2.  Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Authors:  J Jacobs; L-A Korswagen; A M Schilder; L H van Tuyl; B A C Dijkmans; W F Lems; A E Voskuyl; I E M Bultink
Journal:  Osteoporos Int       Date:  2012-10-03       Impact factor: 4.507

Review 3.  Autophagy as a target for glucocorticoid-induced osteoporosis therapy.

Authors:  Gengyang Shen; Hui Ren; Qi Shang; Ting Qiu; Xiang Yu; Zhida Zhang; Jinjing Huang; Wenhua Zhao; Yuzhuo Zhang; Xiaobing Jiang
Journal:  Cell Mol Life Sci       Date:  2018-02-09       Impact factor: 9.261

4.  Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only.

Authors:  C-C Lai; W-S Chen; D-M Chang; Y-P Tsao; T-H Wu; C-T Chou; C-Y Tsai
Journal:  Osteoporos Int       Date:  2014-10-01       Impact factor: 4.507

5.  Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.

Authors:  Gabriela Schmajuk; Edward Yelin; Eliza Chakravarty; Lorene M Nelson; Pantelis Panopolis; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

6.  Reversal of loss of bone mass in old mice treated with mefloquine.

Authors:  Rafael Pacheco-Costa; Hannah M Davis; Emily G Atkinson; Julian E Dilley; Innocent Byiringiro; Mohammad W Aref; Matthew R Allen; Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2018-06-05       Impact factor: 4.398

7.  Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics.

Authors:  Roaa Aljohani; Dafna D Gladman; Jiandong Su; Murray B Urowitz
Journal:  Clin Rheumatol       Date:  2017-06-06       Impact factor: 2.980

Review 8.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

9.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

10.  The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  H P Bhattoa; P Bettembuk; A Balogh; G Szegedi; E Kiss
Journal:  Osteoporos Int       Date:  2003-12-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.